BioPharma Dive
- ‘Selling and marketing snake oil’: The debate over compounded GLP-1sBioPharma Dive ·
Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug.
- White House pulls nomination for FDA nominee OvertonBioPharma Dive ·
The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
- Pfizer leaps into ‘in vivo’ CAR-T with latest China dealBioPharma Dive ·
The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKBioPharma Dive ·
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
- AI drugmaker Isomorphic restocks with $5B fundraiseBioPharma Dive ·
Even as the larger AI industry faces turmoil, investors have given Isomorphic the two largest cash infusions in the biotech sector this year.
- Roche breast cancer pill cleared by FDABioPharma Dive ·
Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.
- Marrow sets out to challenge genetic medicines for severe blood diseasesBioPharma Dive ·
Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.
- Summit shares fall as FDA rejects closely watched PD-1/VEGF drugBioPharma Dive ·
The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
- J&J bets $2.2B on Ollin’s vision loss drugBioPharma Dive ·
The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
- Lilly adds to buyout streak with $1.5B purchase of startup CalytrixBioPharma Dive ·
Lilly’s 15th announced acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
- CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trialBioPharma Dive ·
CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.
- Big-name investors pour $100M into DNA therapeutics developer SeawolfBioPharma Dive ·
The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.
- The infrastructure decisions that will enable tomorrow’s biggest breakthroughsBioPharma Dive ·
Faster drug discovery depends on more than the model. What drug developers need to know about AI.
- Your AI pilots aren’t stalling because of the AI – they’re stalling because of your environmentBioPharma Dive ·
As clinical AI adoption accelerates, trust, traceability and readiness matter more than ever.
- Completing the circle: the next evolution in sustainable pharmaceutical blister packagingBioPharma Dive ·
Discover how innovative PET and PP lidding are advancing sustainable pharmaceutical blister packaging.
- One of Europe’s leading VCs banks a €725M ‘crossover’ fundBioPharma Dive ·
Sofinnova Partners, which has backed the likes of successful drugmakers such as Abivax, Argenx and Verona Pharma, will use the cash to support a new group of later-stage biotechs.
- Novo submits sickle cell drug; Flagship, Gates Foundation deepen tiesBioPharma Dive ·
Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
- This week in charts: Brain drugs are back on venture capitalists’ mindsBioPharma Dive ·
Five neurology-focused startups have together raised around $450 million in the last few weeks. Elsewhere, investors had a muted response to the latest cell therapy research.
- Windward prices $175M IPO to advance China-licensed lung drugsBioPharma Dive ·
The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
- Blackstone bets $1.5B on Pfizer’s obesity drugBioPharma Dive ·
The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
- Bristol Myers research chief to depart in ‘evolution’ of company’s structureBioPharma Dive ·
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
- The FDA has over 1k open jobs — and the staffing shortage is hitting pharmaBioPharma Dive ·
The agency is still recovering from a mass staff exodus last year that left it shorthanded. Here’s what it means for the industry.
- Drug price hikes in Germany could push US costs higher, study saysBioPharma Dive ·
The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.
- AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warningBioPharma Dive ·
The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
- PepGen soars on promising early data for muscular dystrophy drugBioPharma Dive ·
While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.
- Beam’s base editing therapy for sickle cell hits goal in pivotal trialBioPharma Dive ·
The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
- London biotech Oyster harvests $60M for tau-targeting brain drugsBioPharma Dive ·
Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.
- BIO unveils plan for US to remain biotech’s ‘global leader’BioPharma Dive ·
A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.
- Bayer wins FDA nod for a new kind of blood thinnerBioPharma Dive ·
Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
- Vir hepatitis D drug succeeds in first pivotal studyBioPharma Dive ·
A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.
- Argenx to buy peptide platform in potentially billion-dollar dealBioPharma Dive ·
For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.
- Ramaswamy’s biotech baggage haunted his political runBioPharma Dive ·
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
- State incentives for commercial-stage life sciences companiesBioPharma Dive ·
Factor incentives into expansion plans early to improve site decisions, manage commitments and free capital for what comes next.
- Making the ‘impossible’ executable in life sciences constructionBioPharma Dive ·
Why early technical expertise matters when complex life sciences projects challenge convention.
- Translating Phase II success into Phase III readiness takes more than scaleBioPharma Dive ·
The move from Phase II to Phase III is often treated as a clinical milestone, when it is actually a development-wide transition.
- Novartis reveals cancer cases possibly linked to gene therapy ZolgensmaBioPharma Dive ·
The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step downBioPharma Dive ·
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
- This week in charts: 3 drug launches Wall Street is watchingBioPharma Dive ·
The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of medicines highlighted in quarterly earnings this week.
- Medicare will cut billions from 340B, expand site-neutral payments in 2027BioPharma Dive ·
Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some payments between care sites. Hospitals railed against the rule.
- At ASH, drugmakers to showcase early data for three-pronged cancer therapiesBioPharma Dive ·
J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.
- Revolution’s Rasonque off to best cancer drug launch ‘in history’BioPharma Dive ·
Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to draw conclusions about the pancreatic cancer drug’s launch trajectory.
- T-Therapeutics reloads with a $133M megaround for bispecificsBioPharma Dive ·
The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.
- Alethio raises $90M to target rare blood cancersBioPharma Dive ·
The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.
- Sanofi stops development of Nurix-partnered immune drugBioPharma Dive ·
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.
- Novo gets much-needed lift as Wegovy pill tops Wall Street forecastsBioPharma Dive ·
The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.
- CVS to split into two companies in stunning strategic about-faceBioPharma Dive ·
The breakup, which will separate Aetna and Caremark from CVS’ retail pharmacies, is an indictment of the dogma that bigger is always better in the healthcare industry.
- Biopharma likely to climb higher after ‘blue wave,’ analysts sayBioPharma Dive ·
Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.
- Medicare Part D premiums are spiking 50% on average next year, KFF findsBioPharma Dive ·
The health policy think tank urged seniors to shop carefully for prescription drug coverage during Medicare open enrollment, given skyrocketing premiums and wide variance in costs between plans.
- UniQure gets an FDA decision date; Teva scraps brain drug studyBioPharma Dive ·
The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugBioPharma Dive ·
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.